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Abstract
The presence of subclinical levels of psychosis in the general population may imply that schizophrenia is the extreme
expression of more or less continuously distributed traits in the population. In a previous study, we identified five
quantitative measures of schizophrenia (positive, negative, disorganisation, mania, and depression scores). The aim of this
study is to examine the association between a direct measure of genetic risk of schizophrenia and the five quantitative
measures of psychosis. Estimates of the log of the odds ratios of case/control allelic association tests were obtained from the
Psychiatric GWAS Consortium (PGC) (minus our sample) which included genome-wide genotype data of 8,690
schizophrenia cases and 11,831 controls. These data were used to calculate genetic risk scores in 314 schizophrenia
cases and 148 controls from the Netherlands for whom genotype data and quantitative symptom scores were available. The
genetic risk score of schizophrenia was significantly associated with case-control status (p,0.0001). In the case-control
sample, the five psychosis dimensions were found to be significantly associated with genetic risk scores; the correlations
ranged between.15 and.27 (all p,.001). However, these correlations were not significant in schizophrenia cases or controls
separately. While this study confirms the presence of a genetic risk for schizophrenia as categorical diagnostic trait, we did
not find evidence for the genetic risk underlying quantitative schizophrenia symptom dimensions. This does not necessarily
imply that a genetic basis is nonexistent, but does suggest that it is distinct from the polygenic risk score for schizophrenia.
Citation: Derks EM, Vorstman JAS, Ripke S, Kahn RS, The Schizophrenia Psychiatric Genomic Consortium, et al. (2012) Investigation of the Genetic Association
between Quantitative Measures of Psychosis and Schizophrenia: A Polygenic Risk Score Analysis. PLoS ONE 7(6): e37852. doi:10.1371/journal.pone.0037852
Editor: James Bennett Potash, University of Iowa Hospitals & Clinics, United States of America
Received December 23, 2011; Accepted April 29, 2012; Published June 22, 2012
Copyright:  2012 Derks et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Over 40 United States National Institutes of Health grants and similar numbers of government grants from other countries, along with substantial
private and foundation support, enabled this work. We greatly appreciate the sustained efforts of T. Lehner (National Institute of Mental Health) on behalf of the
Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium (PGC). Dr. E.M. Derks is supported by the Netherlands Scientific Organization
(NWO; project number 451-080-010). Statistical analyses were carried out on the Genetic Cluster Computer (http://www.geneticcluster.org) which is financially
supported by the Netherlands Scientific Organization (NWO 480-05-003). The funders had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
Competing Interests: The authors declare the following interests: Eli Lilly funded portions of the genotyping for CATIE and TOP. P.F.S. received research
funding from Eli Lilly in connection with CATIE. T.S.S. received research funding from Eli Lilly and consulting fees from Janssen Pharmaceutica, GlaxoSmithKline
and Bristol-Myers Squibb. J.A.L. received research funding from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutica and
Pfizer and consulting and educational fees from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Janssen
Pharmaceutica, Novartis, Pfizer and Solvay. D.St.C. received research funding from GlaxoSmithKline and Generation Scotland, Genetics Health Initiative. F.A.
received funds from Pfizer, Organon and the Foundation for the National Institutes of Health. D.W.B. has received research support from Shire and Forest, has
been on the speakers’ bureau for Pfizer and has received consulting honoraria from Forest and Jazz. T.W. has received consulting and lecture fees from H.
Lundbeck A/S. O.A.A. has received Speaker’s honorarium from AstraZeneca, Janssen, Bristol-Myers Squibb and GlaxoSmithKline. I.M. has received a Speaker’s
honorarium from Janssen and AstraZeneca. A.K.M. has received consulting fees or honoraria from Eli Lilly & Company, Janssen Pharmaceutica, Merck, Bristol-
Meyers Squibb, Pfizer, PGxHealth (a division of Clinical Data, Inc.), Roche Diagnostics and Vanda Pharmaceuticals and has received research support from Eli Lilly &
Company. T.L. has received consulting fees or honoraria from Merck, Eli Lilly & Company, Golden Helix, Inc., InforMed Insights and PGxHealth (a division of Clinical
Data, Inc.). I.B. has been an advisory board member, consultant and lecturer for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, EGIS, Janssen, H. Lundbeck A/S,
Novartis, Pfizer, Richter and Schering-Plough and received a grant for an investigator-initiated study from H. Lundbeck A/S. J.J.M. has received consulting and
speaker’s fees from Johnson & Johnson, Schering-Plough and Eli Lilly. C.P. has received grant support from Janssen-Cilag, Eli Lilly, Hospira (Mayne) and
AstraZeneca, provided consultancy to Janssen-Cilag, Eli Lilly, Hospira (Mayne), AstraZeneca, Pfizer and Schering-Plough and has undertaken investigator-initiated
studies supported by Eli Lilly, Hospira, Janssen Cilag and AstraZeneca. The Denmark-Aarhus group (The GEMS Stud with principal investigators A.D.B., O.M. and
P.B.M.) received research funding from H. Lundbeck A/S. E.G.J. has served as an unpaid consultant for Eli Lilly. H.S., S.S., and K.S. are employed at deCODE Genetics,
Reykjavik, Iceland. MH is employed at Illumina, Inc., La Jolla, California, USA. PM is employed at NeuroSearch A/S, Ballerup, Denmark. TFO is employed at ARoS
Applied Biotechnology A/S, Skejby, Denmark. There are no patents, products in development or marketed products to declare. This does not alter the authors’
adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.  
* E-mail: e.m.derks@amc.uva.nl
. These authors contributed equally to this work.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e37852
"
"
A full  list  of the authors in the Schizophrenia Psychiatric Genomic Consortium is provided in the Acknowledgements
Introduction
In clinical practice as well as in most research schizophrenia is
conceptualized as a categorical entity, allowing for a distinction in
the population between affected and unaffected. Yet, it has been
proposed that psychotic symptoms, in essence the same as those
observed in individuals with schizophrenia, can also be measured
at subclinical levels in individuals without schizophrenia in the
general population [1]. The concept of a psychosis continuum
implies that schizophrenia is not a categorical disorder, but rather
the extreme expression of otherwise more or less continuously
distributed traits in the population [2]. This view has gained
momentum in recent years. For instance the results of a meta-
analysis showed prevalence rates of psychotic experiences and
symptoms of approximately 4–8% in the general population. In
addition, some of the previously identified risk factors for
schizophrenia, including cannabis, traumatic experiences and
urbanicity, also increase the risk of psychotic experiences in the
non-clinical population [3]. A recent study demonstrated that,
using affectedness of relatives as a proxy, a higher genetic loading
increased the risk of psychotic symptoms in subjects without a
clinical psychotic disorder [4]. To date, no study has explored a
possible correlation between a direct continuous measure of
genetic risk and the continuous psychosis phenotype. The question
is not trivial; finding such correlation would provide strong genetic
evidence for the concept of the psychosis continuum. Inversely, the
demonstration of such correlation would provide a strong
argument for investigating the dimensional scale of psychotic
experiences or symptoms in genetic studies [5].
Reporting on data from the International Schizophrenia
Consortium, Purcell and colleagues presented evidence in support
of a polygenic contribution to schizophrenia [6]. They demon-
strated that the available Genome Wide Association (GWA)
findings are compatible with a large number of shared loci each
with very small odds ratios contributing to disease susceptibility.
Based on the nominally associated alleles in a discovery sample, a
quantitative polygenic risk score was calculated. Subsequently,
when comparing this polygenic risk score between cases and
controls in two independent schizophrenia samples a significantly
higher signal was detected in cases. As was proposed recently by
Plomin and colleagues, the involvement of multiple genes
indicated by the GWAS results for a disorder suggests that the
genetic liability may be distributed quantitatively rather than
qualitatively. This in turn raised the question to which extent this
distribution of polygenic liability is mirrored in a similar
distribution of quantitative traits which compose the disorder [7].
Interestingly, the schizophrenia-derived polygenic risk score was
also shown to be significantly increased in bipolar disorder [6].
This could be interpreted as an indication that genetic liability can
be present with regard to certain symptom domains, rather than
for a specific (categorically defined) syndrome of symptoms. In
other words, it can be argued that the liability for schizophrenia is
composed of co-occurring different genetic liabilities for different
symptom domains. This was supported by recent findings
suggesting the presence of two distinct polygenic risk scores: one
that relates to expression of a ’bipolar disorder-like’ phenotype and
one that is associated with expression of ’schizophrenia-like’
psychotic symptoms [8].
Several studies have investigated whether genetic factors
contribute to symptom dimensions of schizophrenia. Results of
twin studies suggest heritability of symptoms of disorganization [9]
and reality distortion, i.e. hallucinations and/or delusions [10]. A
meta-analysis of the results of studies on symptom concordance in
schizophrenia affected sibling pairs demonstrated significant
correlations within siblings for the dimensions psychomotor
poverty, reality distortion and disorganization, with the latter
showing the highest correlation coefficient [11]. Individual genes
have also been suggested to differentially impact the different
quantitative symptom dimensions (reviewed in [12,13]).
We recently performed factor analyses on 79 symptoms related
to schizophrenia in a large sample of over four thousand subjects,
approximately half of which were healthy controls, while the other
half of the subjects were diagnosed with affective or non affective
psychotic disorders or non psychotic mood disorders [14]. This
was a first attempt to detect latent dimensions for schizophrenia in
a sample that included both psychotic and non-psychotic patients
as well as healthy controls. Our analyses indicated five continuous
dimensions of schizophrenia: positive, negative, disorganisation,
mania, and depression. Importantly, these results have provided us
with measures that express five phenotypic components of the
schizophrenia phenotype as continuous, quantitative traits.
The current study was set up to examine the correlation
between a direct measure of genetic risk of schizophrenia, using
the polygenic risk score, and quantitative measures of schizophre-
nia symptoms, using the five continuous symptom dimensions of
schizophrenia derived from our previous study. We hypothesize a
positive correlation between the polygenic risk score and one or
more of the symptom dimension scales in individuals with and
without a diagnosis of schizophrenia.
We propose that if a significant correlation can be confirmed,
this finding would provide genetic evidence for the psychosis
continuum concept by substantiating the notion proposed by
Plomin et al., namely that the polygenic liability is mirrored in a
similar distribution of quantitative traits which compose the
disorder [7].
Methods
Subjects
From a sample of 715 schizophrenia cases and 643 controls
from The Netherlands, genotypic data of 704 cases and 631
controls passed Quality Control (QC) criteria. We additionally
removed 10 subjects (5 cases and 5 controls) who were indicated as
outliers according to a principal component analysis performed in
EIGENSOFT [15]. This resulted in the final case-control sample
including data of 699 cases and 626 controls. Detailed phenotypic
assessments (i.e., the Comprehensive Assessment of Symptoms and
History (CASH) [16]) was collected in a smaller subsample
including 314 schizophrenia patients and 148 controls. This is the
sample that was used for the analyses of the symptom dimension
scores. The controls had no history of psychiatric disorder. All
patients and controls had at least three grandparents of Dutch
ancestry. The study was approved by the institutional ethical
committee and informed consent was obtained from all partici-
pants. A more detailed description of the inclusion protocol has
been described elsewhere [17].
Genotyping and Quality Control Procedure
All genome-wide genotyping for the GWAS was performed on
Human- Hap550v3 BeadArrays using the Infinium II assay
(Illumina) at the Southern California Genotyping Consortium
(SCGC) at UCLA, Los Angeles, USA.
An extensive quality control (QC) protocol was carried out, the
procedure has been described in full detail [18]. Briefly, SNPs
were included if the missing rate was ,.02, the SNP frequency
difference to HapMap was ,.15, the difference missing rate per
SNP between cases and controls ,.02), and Hardy-Weinberg
Equilibrium was not violated in controls (p,1026). Individuals
Polygenic Risk of Psychosis Dimensions and SCZ
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were included if the missing rate was ,.02. We removed one
member of a pair of observations in case of duplication or cryptic
relatedness. Finally, ten subjects were indicated as outliers
according to the principal component analysis and were removed
from subsequent analyses. The QC protocol resulted in a sample
of 699 cases and 626 controls. The genomic inflation factor of this
sample was 1.02; the QQ plot is shown in Figure S1.
Statistical Analysis
We have previously calculated liability scores on the five
psychosis dimensions (i.e., disorganization, positive, negative,
mania, and depression) in a confirmatory factor analysis including
CASH lifetime rated symptoms from 4,286 subjects. Of these
individuals, N= 1,965 were healthy controls while the remaining
individuals were diagnosed with a psychiatric disorder (N= 1,085
schizophrenia or schizophreniform disorder; N= 160 schizoaffec-
tive disorder; N= 202 bipolar disorder; N=480 major depression;
N= 388 other psychiatric diagnoses) [14]. The subjects included in
the present study are a subset of this larger sample.
Estimates of the log of the odds ratios of case/control allelic
association tests were obtained from the Psychiatric GWAS
Consortium (PGC) sample (but excluding the Utrecht/UCLA
sample) which included Single Nucleotide Polymorphism (SNP)
data (N= 1,241,601) from 8,690 schizophrenia cases and 11,831
controls. SNPs were imputed with HapMap-3 [19] as the
reference panel; confidence metrics in the single datasets were
set at 0.1.
We selected SNPs which were associated with case-control
status below a fixed p-value. Three selection thresholds were
applied; all SNPs associated at p,.5 (selection 1); all SNPs
associated at p,.1 (selection 2); and all SNPs associated at p,.01
(selection 3). LD pruning was applied to select SNPs which are in
approximate linkage equilibrium with each other. We used the –
indep option in PLINK with the default values for the parameters
(i.e., window size of 50 kb, the number of SNPs to shift the
window at each step = 5, and a Variance Inflation Factor (VIF)
threshold of 2 [20]. The total number of SNPs in the three
analyses was 63,935 (selection 1; p,.50); 14,654 (selection 2;
p,.10); 1,954 (selection 3; p,.01).
Genetic risk scores were calculated in PLINK [20] using the
method described by Purcell and colleagues [6].
Briefly, risk scores were calculated based on an individual’s
genotype. For each SNP, the log of the odds ratio of an allele was
multiplied by (0, 1, or 2) depending on the number of risk alleles
that an individual carries. The total polygenic risk score is simply a
sum across SNPs.
In the subsequent analyses, we aimed to correct for the possible
presence of population stratification, by adjusting for the first 10
principal components which were calculated with EIGENSOFT
[15]. A logistic regression analysis was used to investigate whether
the genetic risk score is indeed significantly associated with case-
control status in our independent sample to replicate the results of
Purcell et al. [6]. Nagelkerke R squared was used to compare the
percentage of variance in case-control status explained by the first
10 principal components with the percentage of variance
explained by the first 10 principal components and the genetic
risk score.
Next, we calculated partial correlations between genetic risk
scores (including all SNPs associated at p,.5) and dimension
scores, adjusting for the first 10 principal components in a sample
of 314 schizophrenia cases and 148 controls. This analysis was
performed in the total sample and in cases and controls separately.
Power analyses performed in statistical package R [21] demon-
strated that within cases and controls this study had 80% power to
detect correlations of.22 and.16 respectively, using a type-I error
rate of 5%. We also repeated the case-control analysis in this
smaller subsample to facilitate comparison of the results of the
case-control analysis and the dimension score analyses.
Results
A graphical representation of the distribution of the genetic risk
scores is provided in Figure S2 for cases and controls respectively.
The polygenic risk scores were standardized (i.e., mean= 0
and SD=1) in the total sample. A summary of mean genetic
risk scores by case/control status is provided in Table 1 for
each of the three selections. The logistic regression analysis
indicated that the 10 principal components explained 1.5% of
the variance in case/control status (X2(10) = 15.45, p= .12). The
prediction of case-control status significantly improved by
including the genetic risk factor as a predictor with the
proportion of variance increasing to 2.9%, 4.7%, and 5.1%
based on the inclusion of SNPs associated at p,.01, 0.10, and
0.50, respectively. Substracting the variance explained by the
principal components, this implies that ,1.4 to 3.6% of the
variance in case-control status is explained by the genetic risk
score. The association between genetic risk score and case-
control status was highly significant. For example, using a
threshold of p,0.50, the regression coefficient of the genetic
risk score was 0.36 (Wald = 5.89, p,0.0001). Including all SNPs
associated at p,0.50, the mean genetic risk scores were.13
(SD= .98) and -.18 (SD= .94) in cases and controls, respectively
(see Figure S2). Exclusion of the SNPs in the extended MHC
region (6p21.31–6p22.1) did not affect the results.
Next, we studied the association between psychosis dimen-
sions and genetic risk scores (see Table 1). In the total sample of
cases and controls, the correlations between psychosis dimen-
Table 1. Association of genetic risk scores with symptom dimensions and case-control status across thresholds.
Pearson correlations between genetic risk scores and symptom dimensions
in the total sample and by status
Case-control
status
Positive Total
(case/control)
Negative Total
(case/control)
Disorganisation Total
(case/control)
Mania Total
(case/control)
Depression Total
(case/control)
Mean cases/
mean controls
Genetic risk score: p,.5 .15*(2.01/.06) .19**(.03/.07) .09 (2.09/.05) .12* (2.05/.02) .16** (2.06/.06) .13/2.18**
Genetic risk score: p,.1 .17**(.03/.05) .17**(.03/.08) .08(2.10/.08) .12(2.07/.08) .15*(2.06/.08) .14/2.17**
Genetic risk score: p,.01 .13*(.06/.03) .13*(.04/.02) .03(2.08/2.09) .07(.01/2.06) .11(.03/2.08) .09/2.12**
**p,.001.
*p,.01.
doi:10.1371/journal.pone.0037852.t001
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sions and genetic risk scores range between.09 and.19. These
correlations were statistically significant (p,.01) for the dimen-
sions positive (r = .15), negative (r = .19), mania (r = .12), and
depression (r = .16) while the correlation of the dimensions
disorganization (r = .09) was not statistically significant (p = .04).
The positive correlations are not unexpected since case-control
status is associated both with dimension scores and genetic risk
scores. Therefore, we continued our analyses by testing whether
genetic risk scores are significantly associated with psychosis
dimension scores in the cases and controls separately. In
schizophrenia cases, the correlations ranged between 2.06
and.04 and were not significantly different from zero (all
p..10). Similarly, the correlations in controls were not
significant; the range was between.02 and.07 (all p,.10).
Figure 1a–e show the associations between genetic risk scores
and psychosis dimensions in the total sample with cases and
controls plotted in different colors. As dimension scores were
assessed in a relatively small subsample (24% of the controls and
45% of the cases), we repeated the case-control analysis in this
subsample to facilitate comparison of the results. Including all
SNPs associated at p,.50, 7% of the variance was explained by
the 10 principal components (X2(10) = 22.66, p= .01) which
increased to 13% after inclusion of the genetic risk score
(X2(11) = 43.23, p,.0001).
Discussion
The aim of this study was to investigate the correlation
between the polygenic liability for schizophrenia and quantita-
tive domains of schizophrenia symptoms in schizophrenia cases
and healthy controls. In the current sample, we replicate the
findings by Purcell et al. [6] and show that the polygenic risk
score effectively predicts schizophrenia status in our sample.
Given that both the dimension scores and the genetic scores are
highly associated with case-control status it is not surprising that
the polygenic score was also significantly correlated with each of
the five schizophrenia dimensions when analyzing the entire
sample. The polygenic risk score did not have a significant
correlation with any of the five symptoms dimensions when
cases and controls were analyzed separately. Therefore, we
conclude that the genetic basis of severity differences within
diagnostic subgroups (i.e., cases vs. controls) is not shared with
the genetic basis of case-control status.
There are several possible explanations for this finding. First, in
reality such genetic basis exists but the score alleles (SNPs) used in
the current study do not index severity of the schizophrenia
dimensions selected in the current study. SNPs were selected based
on their association with case-control status and possibly, other
score alleles may be correlated with the schizophrenia dimensions
used in the current study. It is also possible that the used score
alleles may be correlated with schizophrenia dimensions other
than those used in our study. Alternatively, the explained variance
is very small with correlations ,.2, which are potentially not
detected due to a lack of statistical power given the sample size of
this study. A whole different explanation may be that while there is
a continuously distributed genetic liability correlated with schizo-
phrenia dimensions, this genetic liability is not based on common
allelic (SNP) variants. For instance, a continuously distributed
measure based on rare genetic variants or on epigenetic variation
is possible in theory. The most dramatic explanation for our
observation that the schizophrenia polygenic risk score does not
predict severity of symptom dimensions could be the absence of a
continuously distributed genetic liability that explains the observed
psychosis continuum. Please note that this is not inconsistent with
the available evidence indicating a genetic contribution to
schizophrenia dimensions; results so far [11] do not provide
evidence that such genetic contribution is present when adjusting
for case-control status.
It should also be noted that, based on the results of our previous
study [14], we have chosen for the inclusion of five symptom
dimensions. The results of factor analyses largely depend on the
content of the items that are included. If we would have included
items of additional instruments, the number and interpretation of
the resulting factors could have been different. The results of factor
analytical studies have been discussed by Peralta and Cuesta [22]
who showed that the number of factors ranged from 4 to 11,
depending on the content of the items included in the analyses.
The inclusion of additional factors (e.g., psychomotor poverty)
could result in different findings and we hope that other research
groups, who have used different instruments for the assessment of
psychosis will address this question. Future collaborative studies
should aim to further elucidate the genetic basis of quantitative
symptom dimensions by combining symptom ratings assessed in
psychiatric cases (e.g., schizophrenia, bipolar disorder, depression),
and healthy controls.
Supporting Information
Figure S1 QQ plot of the UCLA case-control sample.
This figure plots the expected –log10 (p) at the x-axis and the
observed –log10 (p) at the y-axis.
(DOC)
Figure S2 Distribution of genetic risk scores in schizo-
phrenia cases and controls. This figure shows the distribution
of the genetic risk score in cases and controls.
(DOC)
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